ReviewCNS drugs2011
Atypical antipsychotic-induced weight gain: insights into mechanisms of action.
Review in CNS drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 7 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis.Schizophrenia bulletin · 2025Pooled it
- Eating cognitions, emotions and behaviour under treatment with second generation antipsychotics: A systematic review and meta-analysis.Journal of psychiatric research · 2023Pooled it
- Association between posttraumatic stress disorder and lack of exercise, poor diet, obesity, and co-occuring smoking: A systematic review and meta-analysis.Health psychology : official journal of the Division of Health Psychology, American Psychological Association · 2018Pooled it
- Olanzapine Versus Risperidone in Children and Adolescents with Psychosis: A Meta-Analysis of Randomized Controlled Trials.Journal of child and adolescent psychopharmacology · 2018Pooled it
- Treatment of clozapine-associated weight gain: a systematic review.European journal of clinical pharmacology · 2015Pooled it
- Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2015Pooled it
- A systematic review of antipsychotic drug effects on human gene expression related to risk factors for cardiovascular disease.The pharmacogenomics journal · 2014Pooled it
- Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.Schizophrenia bulletin · 2023Trial
- Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.Psychopharmacology · 2018Trial
- Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.Journal of child and adolescent psychopharmacology · 2013Trial
- Beyond antipsychotic efficacy and toward an individualized therapeutic strategy: analysis of the systemic, metabolic, and inflammatory effects of olanzapine, haloperidol, and their combination in schizophrenic patients.Frontiers in pharmacology · 2026Article
- Weight gain under antipsychotic and mood stabilizing treatment: a narrative review about mechanisms and future options.International journal of bipolar disorders · 2025Review
- Exploring the role of obesity in predicting mental health disorders: analyzing the effects of diagnosis sequence order.BMC psychiatry · 2025Article
- Critical insights into the potential risks of antipsychotic drugs to fish, including through effects on behaviour.Biological reviews of the Cambridge Philosophical Society · 2025Review
- Guideline for pharmacological treatment of schizophrenia 2022.Neuropsychopharmacology reports · 2025Article
- Olanzapine Induces Adipogenesis and Glucose Uptake by Activating Glycolysis and Synergizing with the PI3K-AKT Pathway.Current neuropharmacology · 2025Article
- Exploring the effects of probiotics on olanzapine-induced metabolic syndrome through the gut microbiota.Gut pathogens · 2024Article
- Mechanisms Involved in the Link between Depression, Antidepressant Treatment, and Associated Weight Change.International journal of molecular sciences · 2024Review
- Weight change following diagnosis with psychosis: a retrospective cohort study in Greater Manchester, UK.Annals of general psychiatry · 2024Article
- Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations.Current psychiatry reports · 2023Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prescriptions for second-generation antipsychotics (SGAs) have surpassed those for first-generation agents in the treatment of schizophrenia and bipolar disorder. While SGAs have the benefit of a much reduced risk of causing movement disorders, they have been associated with weight gain and metabolic effects. These adverse reactions are not uncommon, and threaten to have a significant impact on the patient's health over the long-term treatment that the patient requires. Currently, the aetiology of these effects is not known. This article reviews the data exploring the weight gain phenomenon. The literature was reviewed from searches of PubMed and the references of major articles in the field. The SGAs present a heterogeneous risk for weight gain. In addition, different individuals receiving the same drug can exhibit substantially different weight changes. This pattern suggests that a group of factors are associated with the weight gain phenomenon rather than a single mechanism. Coupled with the genetic profile that the patient brings to the treatment, the risk for SGA-induced weight gain will be different for different drugs and different individuals. Targets for exploration of the weight gain phenomenon include receptor interactions involving serotonin, histamine, dopamine, adrenergic, cannabinoid and muscarinic receptors. The association of SGA-induced weight gain and the role of orexigenic and anorexigenic peptides are reviewed. Also, a brief discussion of genetic factors associated with SGA-induced weight gain is presented, including that of the serotonin 5-HT(2C) receptor gene (HTR2C) and the cannabinoid 1 receptor gene (CNR1). The most promising data associated with SGA-induced weight gain include investigations of the histamine H(1), 5-HT(2A), 5-HT(2C), muscarinic M(3) and adrenergic receptors. In addition, work in the genetic area promises to result in a better understanding of the variation in risk associated with different individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.